Variety of qualified clients: CDEC talked over the uncertainty in the volume of people with reasonably intense to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical gurus consulted by CADTH indicated that some clients that are labeled as obtaining gentle or moderate disease can have a intense bleeding phenotype, which mi